Bruker has announced the release of iNTApharma™, a new label-free platform designed to characterize nanoparticles used in mRNA drug development and gene therapy quality control. The technology aims to provide detailed analysis of nanoparticle size, concentration, and stability without the need for fluorescent or radioactive labels.
The platform is intended to support researchers and manufacturers by offering precise and reliable measurements critical for the development and quality assurance of advanced therapeutic products. iNTApharma™ is expected to enhance the efficiency of nanoparticle characterization workflows in pharmaceutical and biotech settings.
**Why this matters**
Accurate nanoparticle characterization is essential for the development and quality control of mRNA drugs and gene therapies, as these therapies rely on nanoparticles for delivery. A label-free approach reduces potential interference and simplifies the analysis process, potentially improving the consistency and safety of these emerging treatments.
Source: NewsData